Joseph M. Unger

17.4k total citations · 5 hit papers
262 papers, 11.1k citations indexed

About

Joseph M. Unger is a scholar working on Oncology, Economics and Econometrics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Joseph M. Unger has authored 262 papers receiving a total of 11.1k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Oncology, 83 papers in Economics and Econometrics and 55 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Joseph M. Unger's work include Health Systems, Economic Evaluations, Quality of Life (61 papers), Economic and Financial Impacts of Cancer (50 papers) and Lymphoma Diagnosis and Treatment (39 papers). Joseph M. Unger is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (61 papers), Economic and Financial Impacts of Cancer (50 papers) and Lymphoma Diagnosis and Treatment (39 papers). Joseph M. Unger collaborates with scholars based in United States, South Africa and Canada. Joseph M. Unger's co-authors include Kathy S. Albain, Dawn L. Hershman, John J. Crowley, Charles A. Coltman, Laura F. Hutchins, Michael LeBlanc, Thomas P. Miller, Richard I. Fisher, Archie Bleyer and Elise D. Cook and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Joseph M. Unger

240 papers receiving 10.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials

1999 1.7k citations Joseph M. Unger, Kathy S. Albain et al. profile →
The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies

2016 401 citations Joseph M. Unger et al. profile →
Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018

2019 365 citations Joseph M. Unger et al. profile →
Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation

2018 343 citations Joseph M. Unger, Riha Vaidya et al. JNCI Journal of the National Cancer Institute profile →
The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies

2016 303 citations Joseph M. Unger et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joseph M. Unger United States	51	5.4k	2.4k	2.2k	1.9k	1.9k	262	11.1k
Stuart M. Lichtman United States	46	4.1k 0.8×	2.5k 1.0×	1.2k 0.6×	1.9k 1.0×	1.2k 0.6×	217	10.9k
Michel P. Coleman United Kingdom	61	6.7k 1.2×	1.3k 0.5×	1.4k 0.6×	2.2k 1.2×	1.3k 0.7×	291	13.3k
Betsy Kohler United States	30	6.2k 1.2×	1.3k 0.5×	1.4k 0.7×	2.9k 1.5×	893 0.5×	61	13.9k
Paul W. Dickman Sweden	59	4.0k 0.7×	1.2k 0.5×	1.4k 0.7×	1.8k 1.0×	710 0.4×	198	12.5k
Lodovico Balducci United States	59	5.8k 1.1×	944 0.4×	1.5k 0.7×	2.9k 1.6×	1.0k 0.5×	283	11.8k
Alok A. Khorana United States	69	5.8k 1.1×	1.4k 0.6×	648 0.3×	2.6k 1.4×	655 0.4×	360	20.8k
Lawrence N. Shulman United States	57	6.7k 1.2×	1.4k 0.6×	1.7k 0.8×	2.1k 1.1×	1.4k 0.7×	332	11.8k
Christina A. Clarke United States	60	6.7k 1.2×	2.6k 1.1×	1.2k 0.5×	1.8k 0.9×	371 0.2×	212	11.3k
Joan L. Warren United States	59	7.8k 1.5×	1.5k 0.6×	1.6k 0.7×	4.7k 2.5×	3.3k 1.8×	147	16.4k
Theresa H.M. Keegan United States	57	4.7k 0.9×	1.0k 0.4×	2.6k 1.2×	1.2k 0.6×	584 0.3×	295	10.9k

Countries citing papers authored by Joseph M. Unger

Since Specialization

Citations

This map shows the geographic impact of Joseph M. Unger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph M. Unger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph M. Unger more than expected).

Fields of papers citing papers by Joseph M. Unger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph M. Unger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph M. Unger. The network helps show where Joseph M. Unger may publish in the future.

Co-authorship network of co-authors of Joseph M. Unger

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph M. Unger. A scholar is included among the top collaborators of Joseph M. Unger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph M. Unger. Joseph M. Unger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Velez, Maria A., et al.. (2025). Characteristics of clinical trials associated with appeal and return on investment to participants: a review and framework. The Oncologist. 30(10).

Unger, Joseph M., Gina L. Mazza, Mohamed I. Elsaid, et al.. (2025). When to adjust for multiplicity in cancer clinical trials. JNCI Monographs. 2025(68). 3–9. 1 indexed citations

Mazza, Gina L., et al.. (2025). Design and analysis considerations for investigating patient subgroups of interest within cancer clinical trials. JNCI Monographs. 2025(68). 22–29. 1 indexed citations

Dressler, Emily V., et al.. (2025). Practical design considerations for cluster randomized controlled trials: lessons learned in community oncology research. JNCI Monographs. 2025(68). 56–64.

Bandos, Hanna, Pedro A. Torres‐Saavedra, Eva Culakova, et al.. (2025). Best practices and pragmatic approaches for patient-reported outcomes and quality of life measures in cancer clinical trials. JNCI Monographs. 2025(68). 14–21. 3 indexed citations

Vaidya, Riha, Cathee Till, N. Lynn Henry, et al.. (2024). Neighborhood socioeconomic deprivation and patient-reported outcomes in symptom management trials for women with breast cancer. Breast Cancer Research and Treatment. 209(3). 603–611.

Presant, Cary A., Cathee Till, Riha Vaidya, et al.. (2024). Smoking prevalence and association with sociodemographic variables in cancer clinical trial participants. Cancer. 131(1). e35560–e35560. 1 indexed citations

Hershman, Dawn L., Riha Vaidya, Cathee Till, et al.. (2024). Socioeconomic Deprivation and Health Care Use in Patients Enrolled in SWOG Cancer Clinical Trials. JAMA Network Open. 7(3). e244008–e244008. 5 indexed citations

Cannioto, Rikki, Kristopher Attwood, Alan D. Hutson, et al.. (2023). Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer. JAMA Network Open. 6(5). e2311673–e2311673. 17 indexed citations

10.

Amengual, Jennifer E., Patrick M. Reagan, Hayder Saeed, et al.. (2023). S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL. Hematological Oncology. 41(S2). 842–843. 1 indexed citations

11.

Hui, David, Amy K. Darke, Katherine A. Guthrie, et al.. (2021). Association Between Health-Related Quality of Life and Progression-Free Survival in Patients With Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials. JCO Oncology Practice. 18(4). e442–e451. 5 indexed citations

12.

Unger, Joseph M., Anna Moseley, Christabel K. Cheung, et al.. (2021). Persistent Disparity: Socioeconomic Deprivation and Cancer Outcomes in Patients Treated in Clinical Trials. Journal of Clinical Oncology. 39(12). 1339–1348. 84 indexed citations

13.

Hershman, Dawn L., Melissa Accordino, Sherry Shen, et al.. (2020). Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. Cancer. 126(7). 1541–1549. 13 indexed citations

14.

Unger, Joseph M., Dawn L. Hershman, Cathee Till, et al.. (2020). “When Offered to Participate”: A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials. JNCI Journal of the National Cancer Institute. 113(3). 244–257. 152 indexed citations

15.

Williams, Grant R., Kathryn E. Weaver, Glenn J. Lesser, et al.. (2020). Capacity to Provide Geriatric Specialty Care for Older Adults in Community Oncology Practices. The Oncologist. 25(12). 1032–1038. 27 indexed citations

16.

Shankaran, Veena, Joseph M. Unger, Amy K. Darke, Dawn L. Hershman, & Scott D. Ramsey. (2020). Design, data linkage, and implementation considerations in the first cooperative group led study assessing financial outcomes in cancer patients and their informal caregivers. Contemporary Clinical Trials. 95. 106037–106037. 5 indexed citations

17.

Press, Oliver W., Joseph M. Unger, Lisa M. Rimsza, et al.. (2013). A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab. Clinical Cancer Research. 19(23). 6624–6632. 32 indexed citations

18.

Hershman, Dawn L., Joseph M. Unger, Katherine D. Crew, et al.. (2013). Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy. Journal of Clinical Oncology. 31(20). 2627–2633. 145 indexed citations

19.

Press, Oliver W., Joseph M. Unger, Lisa M. Rimsza, et al.. (2012). Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus ¹³¹ Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016. Journal of Clinical Oncology. 31(3). 314–320. 123 indexed citations

20.

Rimsza, Lisa M., Michael LeBlanc, Joseph M. Unger, et al.. (2008). Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood. 112(8). 3425–3433. 108 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact